bakeryrogercow
Bluelighter
- Joined
- Nov 7, 2013
- Messages
- 69
Just following up from my last article at Forbes. A top-notch neuropharmacology team were unable to find any opioid receptor agonist activity for W-18 or W-15 at mu, kappa, delta, or nociceptin receptors in vitro. They were unable to even reproduce the mouse analgesia results from the original patent.
http://www.forbes.com/sites/davidkr...r-opioid-as-originally-believed/#19f577fa4121
They did some metabolism studies (in the event W-18 is bioactivated to a potent opioid) and were unable to detect any opioid agonist activity. There were some modest, high-concentration effects on some 5-HT2 receptor subtypes (W-15 antagonism at 2A, 2B and 2C and more potent than W-18 and a concerning effect on the cardiac potassium channel, hERG, suggesting that people should watch out for cardiac arrhythmias.
The report is freely available as a preprint, meaning that it hasn't yet been peer-reviewed. I'm puzzled as to how W-18 might be perceived as an opioid by some users - Cw-a, I'd love to hear your insights.
This is fascinating. What is going on??